Food and Drug Administration · Forecast

Applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics

What it funds

The goal of this funding opportunity announcement is to support applied regulatory science research to evaluate and treat cardiotoxicity of oncology therapeutics. The main outcomes of this work will be publications and presentations; however, FDA staff anticipate substantial involvement in study design and reviewing interim deliverables to ensure that the studies develop practical approaches and solutions that have the potential to inform regulatory decision making in the future. We anticipate organizing regular calls with funded investigators to support the collaboration with FDA - reviewing annual reports would be insufficient to ensure that direction of the research addresses FDA's needs. OCE is interested in supporting research that improve the detection, monitoring and treatment of cardiotoxicity of oncology therapeutics. Specific areas of interest include: -Standardize Definitions: Develop clear definitions for different types and grades of cardiotoxicity -Biomarkers and Imaging: Standardize the use of biomarkers and imaging techniques for assessing cardiotoxicity in oncology trials -Functional Measures: Define consistent criteria for evaluating cardiac function -Monitoring Plan: Develop a standardized cardiotoxicity monitoring plan that specifies the timing of cardiac assessments during the trial. -Risk Stratification: Use a risk stratification model to identify patients at higher risk for cardiotoxicity based on pre-existing conditions and treatment regimens. -Electro…

How to apply

Read the full notice and application package on the official listing, FOR-FD-25-015 on Grants.gov. Questions go to terrin.brown@fda.hhs.gov. Make sure your SAM.gov registration and Grants.gov or agency portal accounts are active well before the deadline, since registration can take several weeks.

Last updated by the agency Nov 20, 2024. Tracked by Federal Runway since Nov 17, 2026. Confirm details on the official notice.

Related opportunities